A couple of thoughts. First of all, the acquisition took place in Q3 and should not effect Q2 earnings. And, secondly, the acquisition telegraphs the need for additional personnel and resources in the UK needed to implement the large pending order of body cams mentioned a couple of months ago. A good thing. And, finally, the acquisition eliminates the 'middle man' on UK sales and will increase margins on the huge pending UK body cam order. To have sold off on this news is ridiculous. This is a buying opportunity for those looking to establish a position in TASR.
Fresno council approves $2.5M for police body cameras, ABC30 reports
Fresno's city council approved more than $2.5M for use in buying 400 body cameras for its police force and will also buy 400 new taser guns from the same company, reported ABC30
gilman. Thanks for that great post. I think you have it exactly right. Law enforcement is going through a true paradigm shift and tasr is right at the heart of it. That is a rare situation. Now, managing the growth is going to be the challenge. I spend my winters in Scottsdale and consequently picked up early on tasr from local reporting. All long holders should do very well. Tasr has been good to me. Thanks again for the post. Have a nice weekend, everybody.
Maryland gov to sign police body camera bill, Washington Post says
Maryland's Republican Governor, Larry Hogan, said he would sign a bill directing the state's police training commission to develop and implement a policy for police to use body cameras, according to The Washington Post. Hogan's decision comes after a Baltimore man died while in police custody, sparking protests in the city. Baltimore's mayor has been lukewarm about the possibility of equipping the city's police force with body cameras.
Expert upbeat on Seattle Genetics Adcetris, says RBC Capital
After meeting with an expert, RBC Capital reports that he believes that off-label use of Seattle Genetics' Adcetris is increasing across a variety of indications. He believes that Adcetris is approvable and has a better chance of becoming a front-line treatment than competing drugs. The firm keeps a $50 price target and Outperform rating on the shares.